U.S. Hotel and Resort REITs Stock News

The market barely flinched at Installed Building Products’ latest earnings, with the stock up less than 1% around US$244. That muted move sits awkwardly against a quarter that put one issue front and center for investors: the valuation premium is now harder to ignore. Installed Building Products is trading on a trailing P/E of 25.7x against lower industry and peer multiples, while earnings over the past year moved only slightly. Q2 did deliver higher revenue of US$777.8m and basic EPS of...

PENN Entertainment reported its second-quarter 2026 results, with revenue rising to US$1.86 billion and net income improving to US$33.1 million, turning around from a loss a year earlier. The quarter also brought record retail revenue, stronger margins, and a raised full-year outlook, while the interactive division narrowed its losses and adjusted its revenue expectations. Now we will examine how PENN’s earnings beat and upgraded full-year outlook influence its pre-existing investment...

In August 2026, ANI Pharmaceuticals reported second-quarter 2026 results showing sales of US$266.04 million and net income of US$24.71 million, alongside reaffirmed full-year net revenue guidance of US$1.08 billion to US$1.14 billion. The sharp year-on-year increase in quarterly earnings per share from continuing operations, on both a basic and diluted basis, highlights how recent performance is tracking against the company’s previously issued full-year outlook. Now we’ll assess how this...

Privia Health Group stock inched up 2.1% to US$22.45 after its Q2 print, a modest move for a company investors have punished over the past month with a slide of about 17%. The market’s first take looks cautious, yet the headline from this quarter is clear. Revenue reached US$632.6m and adjusted EBITDA climbed to US$37.4m, with management lifting full year guidance and pointing to improving margins. For anyone looking beyond today’s quote, the story now turns to whether those margins and cash...

Denali Therapeutics reported past second-quarter 2026 results with US$3.6 million in revenue, a net loss of US$127.55 million, and a reduced loss per share of US$0.68 from continuing operations compared with the prior year. Beyond the headline loss, the company’s first full-quarter commercial revenue from AVLAYAH, expanded payer access, and pro forma cash exceeding US$1.10 billion underscore a growing operational and financial platform for its neurology and rare disease pipeline. We’ll now...

Tandem Diabetes Care stock came into this earnings season on a tear, with the shares already sharply higher over the past month. Today the move turned into a jolt, as the stock jumped another 19% to US$22.38 after the Q2 print. The headline is clear: revenue reached US$254.56m and the company again reported a loss, yet investors locked on to one thing. The market is treating margin repair as the story that matters. Gross margin reached 57%, one of the highest levels Tandem Diabetes Care has...

The market cheered Real Brokerage with a 7.5% pop to US$2.14, yet the headline from this quarter is less about the share price and more about the profit squeeze behind it. Revenue reached US$700.6m, but Real still posted a net loss of US$8.0m for Q2. The company also reported an operating loss of US$7.0m that included US$11.6m of acquisition costs tied to the pending RE/MAX deal. For a stock often viewed as a high growth, low multiple brokerage platform, this gap between strong top line and...

AMN Healthcare Services just ripped 17% higher to about US$36, yet the headline from this quarter is not a clean growth story. Revenue landed at US$673.2m with adjusted EBITDA margin at 10.9%, helped by roughly US$27m of one time items that lifted reported profit and margins. The market is reacting to a sharp improvement from last year and a lower trailing P/E, while largely brushing past how much of this quarter’s strength came from non recurring boosts. The real question for you is how...

MBIA shares slipped about 3% to US$5.11 into the post earnings lull, yet the story the numbers tell is less about sudden collapse and more about a grinding balance sheet strain that refuses to clear. The market is reacting to another quarter of loss making results, with a Q2 GAAP net loss of US$46 million and book value per share still deeply negative. The question for investors is whether this selling reflects a sober read of MBIA’s ongoing capital and equity hole or a reflex move that...

The market reacted strongly to the Halozyme Therapeutics story today. Halozyme shares rose 20% to US$103.12 in regular trading, as traders moved to price in a biotech earnings report that appeared clean and solid rather than speculative. The catalyst was Q2 revenue of US$481m, supported by royalty revenue of US$308m and non-GAAP earnings per share of US$2.28. Management not only exceeded expectations but also raised full-year 2026 revenue and earnings guidance. This shift turned a strong...

WillScot Holdings stock fell 5.6% today, even though the company reported one of its cleanest quarters since last year’s hit to earnings. The market focused on the share price drop, while long term investors may focus on Q2 revenue of US$612.2m and adjusted EBITDA of US$228m with a 37.2% margin, plus a modest lift to full year guidance. Coming into this report, WillScot had already declined about 13% over the past three months. The headline this quarter is simple: profit quality improved,...

Fox Factory Holding entered this earnings report as a bruised story stock with modest recent gains, then jumped 12% to US$21.13 by the close. That kind of move suggests sentiment has shifted. The headline is simple: the company reported Q2 revenue of US$358.1m at the top of guidance and delivered about US$45.5m of adjusted earnings before interest, tax, depreciation and amortization, comfortably ahead of its own range. The market is treating that result as evidence the profit repair plan is...

Kenvue stock barely budged after earnings, inching up about 0.3% to US$19.23, yet the quarter quietly reinforced the core bullish argument. This is a branded consumer health business that many investors view as a steady earner, and the latest numbers again put earnings quality at the center of the story. Q2 basic earnings per share of roughly US$0.24 sat on top of a trailing twelve month earnings rise of about 17%, with net profit margin sitting near 11%. The headline is clear: earnings...

More than US$100b in tariff refunds is now on the table after the Supreme Court struck down IEEPA tariffs, and that kind of cash reshuffle can quietly reshape which large importers come out stronger. Investors watching liquidity, compliance strength and trade exposure may not want to sit this one out. This article walks through 3 large cap U.S. importers exposed to the ruling and how the news could matter for their stocks. The stocks below are just a starting sample, and the full screen...

CPI Card Group stock ripped 13% higher to US$27.72 after its Q2 report, a sharp move for a small payments manufacturer that had already logged strong gains in recent months. The emotional hook for traders is simple. Management raised full year revenue and free cash flow guidance after reporting record first half cash generation and higher gross margins helped by tariff refunds. The market is cheering the headline upgrades. The key question for you is whether that enthusiasm matches a quarter...

Ziff Davis stock jumped 5.7% to US$53.87 into the earnings close, which is a strong move for a company that is still reporting losses from continuing operations. The headline is not the loss. It is the sudden cash firepower created by the US$1.2b sale of the Connectivity business, paired with heavy share repurchases that have already cut the share count by about 11% this year. What you are seeing is a market trying to price a balance sheet and valuation story rather than a clean growth story...

Vistance Networks just jumped 8.3% to US$10.94 in the first full session after earnings, a sharp move for a stock that had been down over the past month and quarter. The headline is not growth at any cost. The story is a profit squeeze in a capital intensive telecom equipment business that needs healthy margins to fund its product roadmap. Q2 adjusted EBITDA for Vistance Networks’ continuing operations came in at US$36m on US$320m of net sales, while Aurora Networks’ EBITDA dropped much...

Willdan Group stock jumped 17% to US$86.24 after its Q2 print, and for once the emotion lines up with the numbers. This is a sentiment reset driven by earnings power. Contract revenue reached US$231.0m and basic earnings per share hit US$1.62, while adjusted EBITDA margins for the quarter stood in the high 20s. For an engineering and energy efficiency specialist that lives and dies on project execution and profitability, this margin step up is the headline. The rest of the report fills in how...

IonQ (NYSE: IONQ) subsidiary Capella secured a significant National Reconnaissance Office Radar Commercial Augmentation contract for commercial SAR data. The award expands IonQ's role in supplying mission critical data and services to U.S. national security and defense customers. The NRO contract adds a new national security oriented revenue stream alongside IonQ's existing government and commercial engagements. This move highlights how quantum and adjacent space data services are starting...

American Realty Investors shares edged 2.5% higher to US$15.36 after the Q2 release, even though the headline story was fresh pressure on profitability. The stock came into earnings after a weak 30 day stretch, and traders quickly focused on the company’s still positive trailing 12 month earnings. The real tension is between that profitable trailing picture and the quarterly income statement, which showed a small loss alongside modest revenue of US$12.9m. With a P/E of 29.7x, sitting above...

Koppers Holdings stock came into this earnings print with a strong three month run, then slipped about 2% to close near US$51 after the report. That small pullback sits awkwardly against the headline number. The company booked Q2 revenue of US$520.1m but reported a sharp quarterly loss, driven by heavy charges tied to accelerating the shutdown of its Stickney facility. The real story for you is not the one day move. It is the margin pressure from cost inflation and the balance sheet strain...

Advanced Drainage Systems dropped about 3% today, which looks odd when you line it up against what just happened in the business. The stock came into this earnings print after a flat month and a modest gain over the past quarter. Yet the company just booked roughly US$1.0b in quarterly revenue and one of its highest ever adjusted earnings before interest, tax, depreciation and amortization margins at 35.8%. The short term mood is cautious. The longer term story is that Advanced Drainage...

Novavax stock inched up about 3% to US$7.95 into the Q2 print, a modest move for a biotech that just posted another quarterly loss. The headline this quarter is not the loss itself. It is the pressure on the income statement as revenue for Q2 came in at US$56.7m and net loss reached US$53.4m. In the very short term traders are reacting to that mix of revenue and red ink. Long term holders are more likely focused on the gap between the current P/S multiple and valuation models that point to a...

Elevance Health stock has delivered a strong 36.9% return over the past year, and the current valuation checks now raise the question of whether that strength is still backed by a discount or already reflected in the price. Over the last 12 months, Elevance Health is up 36.9%, which puts recent buyers in a comfortable position and makes entry price more important for anyone considering the stock today. The company’s push to strengthen its connected cancer care model can support longer term...